What is the recommended treatment approach for acid reflux (gastro‑esophageal reflux disease)?

Acid Reflux Treatment

First-Line Pharmacologic Therapy

Proton pump inhibitors (PPIs) are the most effective first-line treatment for gastroesophageal reflux disease and should be initiated as a 4–8 week trial at standard dose (e.g., omeprazole 20 mg, lansoprazole 30 mg, esomeprazole 40 mg, or pantoprazole 40 mg) taken 30–60 minutes before breakfast. 1, 2, 3

• PPIs provide superior symptom relief and esophagitis healing compared with H₂-receptor antagonists and placebo 1, 2, 4
• Empiric PPI therapy is appropriate for patients with typical heartburn or regurgitation who lack alarm features (dysphagia, weight loss, anemia, bleeding, recurrent vomiting); endoscopy is not required initially 1, 2, 3
• Proper timing is critical—the medication must be taken 30–60 minutes before meals when proton pumps are most active 1, 2, 3

Essential Lifestyle Modifications

Weight loss is the single most effective lifestyle intervention for GERD (Grade B evidence) and should be recommended for all overweight or obese patients with BMI ≥ 25 kg/m². 1, 2, 3, 4

Additional evidence-based lifestyle measures include:

• Elevate the head of the bed by 6–8 inches using blocks or a wedge (not pillows alone) for patients with nighttime symptoms or regurgitation 1, 2, 3
• Avoid lying down for 2–3 hours after meals to reduce esophageal acid exposure 1, 2, 3
• Identify and eliminate individual trigger foods through detailed dietary history rather than imposing broad restrictions; common triggers include coffee, chocolate, alcohol, spicy foods, citrus, tomatoes, and high-fat meals 1, 3, 5, 6
• Limit fat intake to ≤45 grams per day, as high-fat meals delay gastric emptying and increase reflux 1, 2, 6

Treatment Escalation for Persistent Symptoms

If symptoms persist after 4 weeks of standard once-daily PPI therapy:

• Increase to twice-daily PPI dosing (one dose before breakfast, one before dinner) for an additional 4–8 weeks 1, 2, 3
• This escalation provides more complete acid suppression and is particularly important for extraesophageal symptoms 1, 2

Do not add a nocturnal H₂-receptor antagonist to twice-daily PPI therapy—this combination shows no additional efficacy and tachyphylaxis develops within approximately 6 weeks 1, 2

Diagnostic Evaluation

Perform upper endoscopy after 8–12 weeks of optimized twice-daily PPI therapy if symptoms remain uncontrolled, to assess for erosive esophagitis (Los Angeles grade B or higher), Barrett's esophagus, strictures, eosinophilic esophagitis, or alternative diagnoses 1, 2, 3

• If endoscopy is normal but symptoms persist, conduct 24-hour pH monitoring off PPI (withhold therapy 2–4 weeks) to confirm GERD diagnosis and phenotype 1, 2
• Endoscopy is also indicated upfront when alarm features are present (dysphagia, weight loss, anemia, bleeding) 1, 2

Long-Term Management

After symptom control is achieved, taper the PPI to the lowest effective dose that maintains relief. 1, 2, 3, 7

• For patients without endoscopically confirmed erosive esophagitis or Barrett's esophagus, consider gradual dose reduction or on-demand therapy once symptoms are stable 1, 2
• Periodically reassess the need for continued PPI therapy to minimize potential long-term risks (infections, fractures, vitamin B₁₂ deficiency, hypomagnesemia, chronic kidney disease) 1, 2
• If PPI therapy extends beyond 12 months without objective confirmation of GERD, offer endoscopy with prolonged pH monitoring to justify continued treatment 1, 2

Special Considerations for Extraesophageal Symptoms

For patients presenting with chronic cough, laryngitis, globus sensation, or asthma without typical heartburn:

• Initiate twice-daily PPI dosing from the outset and continue for a minimum of 8–12 weeks before assessing response 1, 2, 3
• Implement a strict antireflux diet: ≤45g fat per day, eliminate coffee, tea, soda, chocolate, mints, citrus products, tomatoes, and alcohol 1, 2, 3
• Response rates are significantly lower for extraesophageal symptoms compared with typical GERD, and longer treatment duration is required 1, 2

Therapies to Avoid

Do not use metoclopramide as monotherapy or adjunctive therapy for GERD due to its unfavorable risk-benefit profile, including risk of tardive dyskinesia and extrapyramidal side effects 1, 2, 3

Common Pitfalls

• Do not continue empiric PPI therapy indefinitely without objective testing if symptoms persist beyond 3 months of optimized treatment 1, 2
• Do not assume dietary modification alone will control symptoms—acid suppression is essential for documented esophagitis 1
• Do not use higher-than-standard PPI doses without first optimizing timing and ensuring twice-daily dosing 1